Lantheus Holdings, Inc. (NASDAQ:LNTH) Stake Cut by Vanguard Group Inc.

Vanguard Group Inc. decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,243,262 shares of the medical equipment provider’s stock after selling 176,747 shares during the period. Vanguard Group Inc. owned about 0.10% of Lantheus worth $647,982,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in shares of Lantheus during the fourth quarter valued at approximately $36,183,000. Groupama Asset Managment bought a new position in Lantheus during the 3rd quarter worth $439,000. Swedbank AB increased its position in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after buying an additional 385,000 shares during the period. Keybank National Association OH bought a new stake in Lantheus in the fourth quarter valued at $27,526,000. Finally, Janus Henderson Group PLC boosted its holdings in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after acquiring an additional 257,022 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on LNTH. Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, B. Riley cut their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Trading Down 0.9 %

NASDAQ:LNTH opened at $96.16 on Monday. The company has a 50-day moving average of $93.21 and a 200-day moving average of $96.38. Lantheus Holdings, Inc. has a twelve month low of $58.16 and a twelve month high of $126.89. The firm has a market cap of $6.59 billion, a price-to-earnings ratio of 16.00 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock worth $6,110,806 in the last three months. 1.50% of the stock is currently owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.